Keros Therapeutics
Develops protein therapeutics for neuromuscular disease and blood-cell disorders.
$11.03
After-hours close−0.02 (−0.18%)
At close$11.05(−1.60%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 58.11%18.60M sharesInsiders 2.77%884.9K sharesOther 39.12%12.52M shares
Shares outstanding 32.00M · Float 29.53M · 92.3% free float
Institutions13F, as of Mar 31, 2026
156 holders · 18.60M shares · 27 new positions · 75 increased · 55 reduced · 42 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 2.41M | 7.54% | +121.3K | May 13, 2026 |
| Nantahala Capital Management, LLC | 1.36M | 4.25% | +1.00M | May 15, 2026 |
| Vanguard Capital Management LLC | 831.4K | 2.60% | +831.4Knew | May 15, 2026 |
| Orbimed Advisors LLC | 759.2K | 2.37% | −45.1K | May 15, 2026 |
| Qube Research & Technologies Ltd | 724.9K | 2.27% | −59.0K | May 15, 2026 |
| Jacobs Levy Equity Management, Inc | 706.1K | 2.21% | −62.4K | May 15, 2026 |
| Federated Hermes, Inc. | 689.2K | 2.15% | +34.5K | May 11, 2026 |
| Vanguard Portfolio Management LLC | 682.0K | 2.13% | +682.0Knew | May 8, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 10.10% | 1.99M | 13G | Apr 7, 2026 ↗ |
| Nantahala Capital Management, LLC | 6.90% | 1.36M | 13G | May 15, 2026 ↗ |
| Madison Avenue Partners, LP | 6.40% | 2.61M | 13G | May 14, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Jasbir Seehra | director, officer: CHIEF EXECUTIVE OFFICER | 440.7K | 1.38% | Apr 6, 2026 |
| Julius Knowles | director | 113.2K | 0.35% | Jun 8, 2026 |
| Carl L. Gordon | director | 50.3K | 0.16% | Dec 18, 2025 |
| Annita Tanini | officer: Corp. Controller & VP, Finance | 45.1K | 0.14% | Aug 20, 2026 |
| Orbimed Advisors LLC | director | 45.1K | 0.14% | Dec 18, 2025 |
| Keith Regnante | officer: CHIEF FINANCIAL OFFICER | 39.3K | 0.12% | Feb 20, 2026 |
| Esther Cho | officer: Chief Legal Officer | 35.8K | 0.11% | Aug 20, 2026 |
| Lorena Raquel Lerner | officer: Chief Scientific Officer | 27.6K | 0.09% | Aug 20, 2026 |
| Jean Jacques Bienaime | director | 19.6K | 0.06% | Aug 19, 2026 |
| Anne Prener | director | 13.8K | 0.04% | Jul 6, 2026 |
1 ten-percent owner holds 1.38M shares by Form 4, outside the officers-and-directors figure above · 4 people have not refiled in the last 18 months (1.58M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 18, 2026 | Charles W. Newtondirector | Sale | 551 | $10.30 | 12,114 |
| Aug 18, 2026 | Esther Choofficer: Chief Legal Officer | Sale | 4,485 | $10.29 | 35,770 |
| Aug 18, 2026 | Lorena Raquel Lernerofficer: Chief Scientific Officer | Sale | 3,568 | $10.29 | 27,559 |
| Aug 18, 2026 | Annita Taniniofficer: Corp. Controller & VP, Finance | Sale | 1,224 | $10.29 | 45,144 |
| Aug 17, 2026 | Jean Jacques Bienaimedirector | Purchase | 1,000 | $10.27 | 19,592 |
| Jul 15, 2026 | Jean Jacques Bienaimedirector | Purchase | 1,000 | $10.61 | 18,592 |
| Jun 15, 2026 | Jean Jacques Bienaimedirector | Purchase | 1,000 | $10.19 | 17,592 |
| Jun 11, 2026 | Charles W. Newtondirector | Sale | 550 | $10.04 | 12,665 |
| Jun 4, 2026 | Julius Knowlesdirector | Sale | 2,625 | $10.73 | 10,958 |
| Jun 4, 2026 | Nima Farzandirector | Sale | 2,625 | $10.73 | 9,767 |
CongressHouse and Senate disclosures
Not reported.